Skip to main content
Premium Trial:

Request an Annual Quote

Debiopharm, Partner to Accelerate Precision Cancer Drug Development

NEW YORK – Debiopharm will apply's artificial intelligence digital cells lab platform to develop new precision cancer drugs, the companies said on Wednesday.

Within the partnership, San Diego-based will work with Debiopharm to advance its cancer drugs in new indications, identify opportunities to combine these agents with other therapies in development, compare the activity of different treatments, validate drug mechanisms, and identify predictive biomarkers.'s AI Digital Cells Lab is based on generative distributed reasoning AI. Unlike more familiar machine learning-based AI systems, generative distributed reasoning AI is designed to use human-like reasoning informed by data and deep domain knowledge to generate models rather than texts, images, or videos. The firm's AI Digital Cells Lab produces models of human cells, called human digital clones, based on gene-expression data that can be used in drug discovery and development research.

Lausanne, Switzerland-headquartered Debiopharm's drug development pipeline includes several investigational oncology treatments, including the CA IX-targeted radiotherapy Debio 0228, the IAP antagonist xevinapant (Debio 1143) for head and neck cancer, and the Wee1 kinase inhibitor Debio 0123. The company began a Phase I/II trial of Debio 0228 in patients with CA IX-expressing solid tumors in March 2023, and has inked partnerships with SunRock Biopharma and Nucleai for drug and biomarker discovery.

In its deal with SunRock, Debiopharm is jointly developing antibody-drug conjugates for treating cancer including tumors expressing HER2 and HER3, and with the AI firm Nucleai, Debiopharm is searching for biomarkers to identify best responders to one of its clinical-stage oncology assets.